Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588283 · ClinicalTrials.gov registry record · Phase 3
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
A Phase 3 study of Obesity and Psoriasis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06588283: Active Phase 3 study of Obesity and Psoriasis, sponsored by Eli Lilly and Company.
NCT06588283 is a Phase 3 study of Obesity and Psoriasis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588283, a Phase 3 study of Obesity and Psoriasis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
Primary Outcome
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \*
Interventions
- DRUG Tirzepatide
- DRUG Ixekizumab
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research Inc - Fountain Valley
- Avance Clinical Trials - Laguna Niguel
- Metropolis Dermatology - Los Angeles
- Dermatology Research Associates - Los Angeles
- Northridge Clinical Trials - Northridge
- Cura Clinical Research - Oxnard - Oxnard
- Integrative Skin Science and Research - Location 2 - Sacramento
- Therapeutics Clinical Research - San Diego
Florida
- Life Clinical Trials - Coral Springs
- Alliance for Multispecialty Research, LLC - Fort Myers
- NeoClinical Research - Hialeah
- Skin Care Research - Hollywood
- Encore Medical Research - Hollywood
- Solutions Through Advanced Research - Jacksonville
Arizona
- Medical Dermatology Specialists - Phoenix
- Scottsdale Clinical Trials - Scottsdale
- Yuma Clinical Trials - Yuma
Alabama
- Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology - Birmingham
Arkansas
- Johnson Dermatology - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT06588283 still lists
NCT06588283 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06588283 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06588283 about?
NCT06588283 is a clinical study titled "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight". The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in th...
What is the current status of trial NCT06588283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2024-09-30. Estimated completion is 2026-05.
What conditions does trial NCT06588283 study?
This clinical trial studies the following conditions: Obesity, Psoriasis.
What interventions are being tested in trial NCT06588283?
The interventions under investigation include: Tirzepatide (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT06588283?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588283 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06588283's enrollment target sits among peer trials
250 255th of 1053 higher than 789 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI